Description: Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France.
Home Page: valeriotx.com
49, boulevard du GEnEral Martial Valin
Paris,
75015
France
Phone:
33 1 70 38 33 99
Officers
| Name | Title |
|---|---|
| Mr. Julien Miara | CEO & Chairman |
| Dr. Shefali Agarwal M.D., MPH | President |
| Ms. Joyce Carey | Executive Director of Finance and Head of FP&A |
| Ms. Robin Sutherland | VP & Global Head of Human Resources |
| Mr. Michel Forest | Chief Pharmacist & Quality Assurance Director |
| Ms. Huiping Jiang | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Mr. Wael Jdey Ph.D. | Head of Preclinical |
| Dr. Donna Cabral-Lilly Ph.D. | VP & Head of CMC |
| Ms. Pam Slatcher | Head of Global PV |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4845 |
| Price-to-Sales TTM: | 5.885 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |